JP2012176958A - Treatment of smooth muscle hyperactivity by (r)-oxybutynin and (r)-desethyloxybutynin - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a method for minimizing side effects relating to administration of racemic oxybutynin or racemic desethyloxybutynin.SOLUTION: An optically pure R(-)-isomer of oxybutynin and desethyloxybutynin is used for treatment of cholinergic property mediated smooth muscle hyperactivity to alleviate symptoms relating to bladder smooth muscle hyperactivity such as urinary incontinence and gastrointestinal smooth muscle hyperactivity such as anaphylactic enteritis syndrome.

Description

  The present invention relates to the R (−)-isomer of optically active 4-diethylamino-2-butynyl cyclohexylphenyl glycolate and its termed R (−)-4-ethylamino-2-butynyl cyclohexylphenyl glycolate It relates to optically active metabolites. The compound 4-diethylamino-2-butynyl cyclohexylphenyl glycolate has a common name, oxybutynin (OXY), is an approved drug for the management of urinary incontinence, and is also useful for the treatment of gastrointestinal smooth muscle hyperfunction.

The compound 4-ethylamino-2-butynyl cyclohexylphenyl glycolate is called desethyloxybutynin (DEO) and has the following chemical structure:

  Racemic oxybutynin (OXY) has been used therapeutically, for example, in the treatment of smooth muscle hyperactivity such as urinary incontinence. OXY exerts an antispasmodic effect by inhibiting acetylcholine receptors on smooth muscle. OXY is selective for muscarinic acetylcholine receptors over nicotinic receptors, and as a result no blocking effect at the skeletal neuromuscular junction has been observed.

  Clinical studies have shown that in patients with conditions characterized by involuntary bladder contractions, OXY increases bladder capacity, decreases the frequency of involuntary contractions of the detrusor, and delays the initial desire to urinate. OXY is therefore useful for the treatment and prevention of both incontinence and frequent voluntary urination. The antimuscarinic side effects of OXY, such as mydriasis, dry mouth and tachycardia, cannot be avoided with this drug because of its therapeutic antimuscarinic effect (Lish et al., 1965).

Racemic oxybutynin consists of 50% R (−)-oxybutynin and 50% S (+)-oxybutynin. In practice, all of the anticholinergic activity of OXY is in the R (−)-isomer, and the S (+)-isomer has been shown to have little anticholinergic activity of the drug. (Noronha-Blob et al., 1991 and Smith et al., 1998).
One clinically important metabolite of OXY has been identified in humans following OXY administration and is referred to as desethyloxybutynin (DEO). A second metabolite called N-oxide-oxybutynin is a therapeutically active compound, but is chemically unstable (Lindeke et al. 1981).

  It was unexpectedly discovered here that the S (+)-isomer of oxybutynin has the significant cardiovascular inhibitory activity of oxybutynin. This unwanted side effect is important in all patients who have been given racemates, particularly elderly patients or patients who have previously had cardiovascular problems. The R (−)-isomer of oxybutynin was completely unexpected but was found to be better tolerated than the S (+)-isomer when administered to experimental animals. Furthermore, it has been discovered that the R (−)-isomer of oxybutynin and desethyloxybutynin provides a better therapeutic effect when compared to its corresponding racemate and its optical enantiomer. The active compounds of the invention are therefore the R (−)-isomer of oxybutynin and the R (−)-isomer of desethyloxybutynin.

Chemistry
Racemic oxybutynin is 4-diethylamino-2-butynyl_-cyclohexyl -_- hydroxy-benzene acetate, also known as 4-diethylamino-2-butynyl cyclohexylphenyl glycolate, also referred to herein as OXY. The generic name given to the racemic oxybutynin hydrochloride by the USAN Council is oxybutynin chloride ; sold under the name Ditropan ^R.

R (-)-oxybutynin is R (-)-4-diethylamino-2-butynyl_-cyclohexyl -_- hydroxy-benzeneacetate, again referred to as R-OXY. The generic name for this compound and its salts is not known.

Racemic desethyloxybutynin is 4-ethylamino-2-butynyl cyclohexylphenyl glycolate and is a known metabolite of oxybutynin (Hughes KM et al. 1992). This compound is again referred to as DEO. The generic name for this compound and its salts is not known.

R (-)-desethyloxybutynin is R (-)-4-ethylamino-2-butynyl cyclohexylphenyl glycolate, again referred to as R-DEO. The generic name for this compound and its salts is not known.

The entire process for making R-OXY includes the following steps:
(A) Preparation of 4-diethylamino-2-butynyl chloride from dichlorobutyne (b) A single R-enantiomer of cyclohexylphenylglycolic acid and the prepared 4-diethylamino-2-butynyl chloride by standard esterification techniques. React to give the R-enantiomer of 4-diethylamino-2-butynyl cyclohexylphenyl glycolate.

The process for manufacturing R-DEO includes the following steps:
(A) Preparation of side chain 4-ethylamino-2-butynyl chloride from dichlorobutyne (b) Using standard esterification techniques, the R-enantiomer of cyclohexylphenylglycolic acid is reacted with the selected side chain to produce R ( -)-4-Ethylamino-2-butynyl R-enantiomer of cyclohexylphenyl glycolate is produced.

Another process for preparing the compounds of the invention involves the preparation of hydroxylated side chains instead of the halogenated side chains.
Racemic cyclohexyl phenylglycolic acid is available from SIPSY Chem Corp. , 2137 Route 33, Suite 2, Hamilton Square, NJ 08690, commercially available.

  The R-enantiomer of cyclohexylphenylglycolic acid can be obtained by resolution of racemic cyclohexylphenylglycolic acid or by chiral synthesis.

R-OXY and R-DEO can also be prepared by resolution from racemic materials using conventional means such as fractional crystallization of diastereomeric salts with chiral acids. Other standard resolution methods known to those skilled in the art include (but are not limited to) simple crystallization and chromatography on chiral substrates and can be used.
The degree of prophylactic or therapeutic dose of the compounds of the present invention in the acute or chronic management of dosage, dosage form, pharmaceutical composition disease will vary with the severity and nature of the condition to be treated and the route of administration. The dose and frequency of administration will also vary according to the age, weight and response of the individual patient. In general, the total daily dose will range from about 1 mg to about 100 mg for a compound of the invention for a condition described herein in a single or divided dose (preferably in divided doses). In managing the patient, treatment should begin at a lower dose, perhaps about 0.5 mg to about 25 mg, and may be increased to about 200 mg, depending on the patient's overall response. It is further recommended that patients over the age of 65 and patients with defective renal or liver function receive low doses and that they are titrated based on individual response and plasma drug levels. It will be apparent to those skilled in the art that it may be necessary to use dosages outside these ranges. It should also be noted that the clinician or treating physician will know how and when to interrupt, adjust or terminate therapy in relation to individual patient responses. The terms “therapeutically effective amount” and “an amount sufficient to treat urinary incontinence but insufficient to cause side effects” are encompassed by the above dosage and frequency regimen. .

  Any suitable route of administration may be employed for providing a patient with an effective dosage of a compound of the present invention. For example, oral, sublingual, rectal, parenteral (subcutaneous, intramuscular, intravenous), intraocular, transdermal, aerosol, and similar forms of administration may be used. Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, microencapsulation systems, sprays, transdermal delivery systems and the like.

  The pharmaceutical composition of the present invention comprises the compound of the present invention or a pharmaceutically acceptable salt or solvate thereof as an active ingredient, and a pharmaceutically acceptable carrier and optionally other therapeutic ingredients. Also good.

  The term “pharmaceutically acceptable salt or solvate” or “pharmaceutically acceptable salt or solvate” refers to a salt or solvate prepared from a pharmaceutically acceptable non-toxic acid. Yes. Suitable pharmaceutically acceptable acid addition salts of the compounds of the present invention include acetic acid, benzenesulfonic acid (besylate), benzoic acid, camphorsulfonic acid, citric acid, ethanesulfonic acid, fumaric acid, gluconic acid, glutamic acid, odor Hydrofluoric acid, hydrochloric acid, isethionic acid, lactic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, mucinic acid, nitric acid, pamoic acid, patothenic acid, phosphoric acid, succinic acid, sulfuric acid, tartaric acid, p-toluenesulfonic acid Etc. are included. Hydrochloride is particularly preferred.

  The compositions of the present invention include suspensions, solutions, elixirs or solid dosage forms. Carriers such as starch, sugar and microcellulose, diluents, granulating agents, lubricants, binders, disintegrants etc. are suitable for oral solid preparations (such as powders, capsules and tablets), Oral solid formulations are preferred over oral liquid formulations.

  Because of their ease of administration, tablets and capsules have the advantage of oral single dosage forms, in which case solid pharmaceutical carriers are employed. If desired, tablets may be coated by standard aqueous or nonaqueous techniques.

  In addition to the conventional dosage forms set forth above, the compounds of the present invention are prepared from U.S. Pat. Nos. 3,845,770; 3.916,899; 3,536,809; 3,598,123; and 4,008.719. And may be administered by controlled release means and delivery devices as described in PCT application WO 92/20377, the disclosures of which are hereby incorporated by reference.

  Pharmaceutical compositions of the present invention suitable for oral administration are given as isolated single dosage forms such as capsules, cachets or tablets, each as a powder or granules, or as a solution or aqueous liquid, non-aqueous solution, oil-in-water. As a suspension in an emulsion or water-in-oil liquid emulsion, it contains a predetermined amount of the active ingredient. Such compositions are prepared by any method of pharmacology, but all methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more necessary ingredients. In general, the composition comprises an equal and thorough mixing of the active ingredient with a liquid carrier or a finely divided solid carrier or both, as known for racemic mixtures, followed by if necessary Prepared by shaping the product into the desired appearance.

  For example, a tablet is prepared by compression or molding, optionally with one or more accessory ingredients. Compressed tablets are prepared by compressing a free-flowing active ingredient such as a powder or granules in a suitable machine, optionally with a binder, lubricant, inert diluent, surfactant or dispersant. Is done. Molded tablets are made by molding, in a suitable machine, a mixture of the wet powdered compound and an inert liquid diluent. All of the above techniques are well known to those skilled in the pharmaceutical arts. Each tablet will contain from about 0.5 mg to about 25 mg of the active ingredient.

Example 1
Oral single dosage form

Selected compounds of the invention were blended with lactose and cellulose until a homogeneous blend was formed. Lake was added and further mixed. Finally, calcium stearate was blended and the resulting mixture was compressed into tablets using a 9/32 inch (7 mm) shallow concave punch. Other strength tablets may be prepared by varying the prescribed amounts relative to the active ingredient excipients or to the final weight of the tablet.

The surprising utility of the compounds of the present invention was established by the following studies.
Example 2
Pharmacological research
Materials and Methods Acute toxicity in mice Experiments were performed in conscious albino mice, in which test compounds were administered at escalating doses intravenously or orally.
2. Ligand binding studies: muscarinic receptors Experiments are performed on membranes prepared from SF9 cells infected with baculovirus to express human recombinant muscarinic receptor subtypes. After incubation and washing with the test article and the appropriate radioligand, bound radioactivity is determined in a liquid scintillation counter using a commercially available scintillation cocktail. Specific radioligand binding to each receptor is defined as the difference between total binding and nonspecific binding determined in the presence of excess unlabeled ligand. IC ₅₀ values (concentration required for 50% inhibition of specific binding) are determined by nonlinear regression analysis of competition curves. These parameters are obtained by curve fitting using Sigmaplot ^™ software.
3. Cardiac side effect studies Male guinea pigs (450-600 g) are anesthetized with freshly prepared dialletane sodium. The jugular vein is catheterized for iv administration of the test drug, and the trachea is exposed and cannulated. The dermal electrode is placed in an appropriate location for Lead II electrocardiogram recording, monitored with a Glass Polygraph recorder, and set at a paper feed rate of 50 mm / sec. The animals are allowed to stabilize for 30 minutes after completion of the surgery, and three EKG recordings are made at 10 minute intervals. The animals are then given a test compound dose or vehicle by intravenous infusion over 30 minutes. EKG recording is used to determine QT interval and heart rate. To compensate for heart rate variability, the QTc interval is calculated from the QT- and RR-intervals as is known to those skilled in the art. QTc prolongation is an indicator of sustained potency caused by inhibition of delayed rectifier potassium channels. Prolongation of QTc is a known cause of torsade de pointe ventricular fibrillation by drugs such as terodiline, terfenadine and astemizole (currently withdrawn from the market).
4). Functional characterization of antimuscarinic / antispastic activity A strip of bladder smooth muscle or intestinal smooth muscle tissue is removed from the body of a male Hartley guinea pig weighing 400-600 g. Experiments are performed using methods similar to those described by Kachu et al, 1988 and Noronha-Blob and Kachu, 1991. Strips (approximately 10 mm long and 1.5 mm wide) from bladder tissue are removed from the bladder body of a male Hartley guinea pig weighing 400-600 g. Guinea pig colon longitudinal smooth muscle preparations are prepared as is known in the art (Ata Physiol Scan 64 : 15-27, 1965). Tissue suspended in oxygenated buffer of the following composition and in mM: NaCl, 133; KCl, 4.7; CaC1 2, 2.5; MgSO 4, 0.6; NaH 2 PO 4, 1.3; NaHCO ₃ , 16.3; and glucose 7.7, or a similar composition. These are kept at 37.5 ° C. The shrinkage is recorded on an ink writing multipurpose record using an isometric transducer (model FT-10).

  In each experiment, up to 7 bladder strips or up to 4 intestinal smooth muscle strips are removed from a single animal, suspended in a tissue chamber and soaked for 1 hour before proceeding with the experiment. Equilibrate.

Each tissue strip in response to exposure to tissue medium in which NaCl is replaced with KCl to obtain a KCl concentration of 137.7 mM in the medium to assess the viability of each tissue and to serve as a reference system The contraction of is first recorded. This is followed by returning to the standard medium, and then gradually increasing the concentration of carbachol and exposing to each concentration until another peak response is recorded. Next, one strip exposed to the test solution that served as an untreated strip and / or control tissue is left, and each of the remaining strips is exposed to one concentration of antagonist for 1 hour. Finally, a second response to the increased carbachol concentration followed by exposure to 137.7 mM KCl is recorded. In order to determine if the antagonist reduces the peak response to the agonist, the peak stress generated by each strip during the second set of determinations was generated during the first concentration-effect determination. Expressed as a percentage of peak stress. The resulting data is then analyzed using standard statistical methodologies for each antagonist.
Equivalents Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents include many pharmaceutically acceptable salts or solvated forms such as sulfate, fumarate, hydrobromide, hydrochloride, hydrogen dichloride, methanesulfonate, hydroxy Merck Index 11th edition (1989), items 9089, 209, 3927, 4628, 8223, 5053, 5836, including naphthoate, chlorotheophylline or, where appropriate, one or the other of its hydrate forms. 8142, 2347, 7765, 1840, 9720, 7461, 1317, 4159 and 963 and references cited therein, and Am. Rev. Resp. Dis. 1988, 137: (4; 2/2) 32. Such equivalents also include the co-administration of at least one compound of the present invention with any other agent used to combat disease in mammals as described in this document. Such equivalents also include co-administration of at least one compound of the invention with any other compound or agent that would be used in combination with a medicament for urinary incontinence or hyperintestinal function. Yes. Those skilled in the pharmaceutical arts also understand that doses higher or lower than those shown herein may be suitable and that administration may be given more or less frequently than suggested herein. Will do.

One skilled in the art will also appreciate that smooth muscle hyperfunction may be expressed in various types of smooth muscle, namely smooth muscle of the bladder, gastrointestinal tract, kidney and gallbladder.
Persons skilled in the art know that hyperintestinal dysfunction includes irritable bowel syndrome (IBS), urinary bladder dysfunction includes urge urinary incontinence, and kidney and gallbladder and biliary hyperfunction cause kidney and gallstone pain Will be understood to include.

  Those skilled in pharmacology have certain pharmacological properties such as antimuscarinic activity against various receptor types, calcium antagonistic activity, antispasmodic activity against various types of smooth muscle, etc. Will be useful for applications other than those listed here. Such an application is equivalent to the particular embodiments of the invention described herein.

  All equivalents are intended to be included in the present invention.

Claims (14)

  A method for treating urinary incontinence and other motility disorders associated with urinary roads while reducing the burden of concomitant adverse effects associated with racemic oxybutynin, to humans in need of such treatment Administering a therapeutically effective amount of R (-)-4-diethylamino-2-butynyl cyclohexylphenyl glycolate or a pharmaceutically acceptable salt or solvate thereof substantially free of the corresponding S-enantiomer A method consisting of:   A method for treating irritable bowel syndrome (IBS) and other motility disorders associated with the gastrointestinal tract while reducing or eliminating the burden of concomitant adverse cardiac side effects associated with the parent compound, comprising: Therapeutic treatment of R (−)-4-diethylamino-2-butynyl cyclohexylphenyl glycolate or a pharmaceutically acceptable salt or solvate thereof substantially free of the corresponding S-enantiomer to the mammal in need A method comprising administering an effective amount.   A method for treating urinary incontinence and other motility disorders associated with urinary roads while reducing the burden of concomitant adverse effects associated with racemic oxybutynin, to humans in need of such treatment Administering a therapeutically effective amount of R (-)-4-ethylamino-2-butynyl cyclohexylphenyl glycolate or a pharmaceutically acceptable salt or solvate thereof substantially free of the corresponding S-enantiomer A method consisting of:   A method for treating irritable bowel syndrome (IBS) and other motility disorders associated with the gastrointestinal tract while reducing or eliminating the burden of concomitant adverse cardiac side effects associated with the parent compound, comprising: Treatment of R (-)-4-ethylamino-2-butynyl cyclohexylphenyl glycolate or a pharmaceutically acceptable salt or solvate thereof substantially free of the corresponding S-enantiomer to a mammal in need A method comprising administering a pharmaceutically effective amount.   R (−)-4-diethylamino-2-butynyl cyclohexylphenyl glycolate or a pharmaceutically acceptable salt or solvate thereof is administered by inhalation or parenterally, transdermally, rectally, sublingually or orally. The method according to claim 1 and 2.   R (−)-4-ethylamino-2-butynyl cyclohexylphenyl glycolate or a pharmaceutically acceptable salt or solvate thereof is administered by inhalation or parenterally, transdermally, rectally, sublingually or orally. The method according to claim 3 and 4.   The method according to claims 1 and 2, wherein R (-)-4-diethylamino-2-butynyl cyclohexylphenyl glycolate or a pharmaceutically acceptable salt or solvate thereof is administered orally.   The method according to claims 3 and 4, wherein R (-)-4-ethylamino-2-butynyl cyclohexylphenyl glycolate or a pharmaceutically acceptable salt or solvate thereof is administered orally.   3. The method of claims 1 and 2, wherein R (-)-4-diethylamino-2-butynyl cyclohexylphenyl glycolate or a pharmaceutically acceptable salt or solvate thereof is administered orally in an extended release formulation.   The method according to claims 3 and 4, wherein R (-)-4-ethylamino-2-butynyl cyclohexylphenyl glycolate or a pharmaceutically acceptable salt or solvate thereof is administered orally in an extended release formulation. .   The method according to claims 1 and 2, wherein R (-)-4-diethylamino-2-butynyl cyclohexylphenyl glycolate or a pharmaceutically acceptable salt or solvate thereof is administered transdermally.   The method according to claims 3 and 4, wherein R (-)-4-ethylamino-2-butynyl cyclohexylphenyl glycolate or a pharmaceutically acceptable salt or solvate thereof is administered transdermally.   3. The method of claims 1 and 2, wherein R (-)-4-diethylamino-2-butynyl cyclohexylphenyl glycolate or a pharmaceutically acceptable salt or solvate thereof is administered from about 1 mg to about 200 mg per day.   5. The method of claims 3 and 4, wherein R (-)-4-ethylamino-2-butynyl cyclohexylphenyl glycolate or a pharmaceutically acceptable salt or solvate thereof is administered from about 1 mg to about 200 mg per day. .